Newsfile Corp
10 Nov 2025, 23:53 UTC · 44w ago
Verdict
Headline takes no side. We score JSPR −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Jasper Therapeutics is halting the ETESIAN study and pausing development in asthma and SCID due to drug product lot issues.
So whatThe termination of multiple clinical programs significantly reduces the company's pipeline value and probability of future regulatory approvals.
More negative than 99% of claims this week
Jasper is implementing cost-reduction measures and potential restructuring to extend its cash runway after failing to meet its previously stated target of extending through Q3 2025.
So whatFinancial instability and the need for urgent restructuring suggest liquidity risks and a failure of previous management guidance.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 96% of claims this week
A federal securities class action lawsuit alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations.
More negative than 87% of claims this week
Data from the BEACON Study was confounded by issues with a specific drug product lot used in two dose cohorts.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities class action lawsuit following a 55% stock price drop, clinical trial failures, and manufacturing quality issues.
More negative than 80% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
More negative than 80% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−65.3%
Price agrees with the score
$0.6178 vs $1.78 close before publication (Nov 10) · not market-adjusted
JSPR chart →
